FDA Urges Lower Target for ESA Use; Market Could Drop By More Than Half.
CMS Launches National Coverage Analysis, Citing FDA’s Black Box Warning on ESAs.
FDA Purges Quality of Life Claims from Oncology Label for ESAs.
Amgen Says It Can Demonstrate Safety of Existing Hg Target.
If You Were On ODAC: Experts Suggest Questions For May 10 Advisory Meeting.
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Early-onset colorectal cancer is behaving like a new, biologically distinct disease, researchers note
One woman’s pregnancy shows how this distinction matters - More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data in ACS guideline support greater use of noninvasive tests to ease system strain, save lives - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- David Gius assumes role of director of the University of Cincinnati Cancer Center









